ArticleAnnals of surgical oncology2026
Smoking Status and Response to Total Neoadjuvant Therapy for Rectal Cancer: A National Cohort Study.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTobacco smoking is prevalent among patients with rectal cancer, yet its effect on pathologic response to total neoadjuvant therapy (TNT) remains unknown. This study evaluated the association between smoking status and pathologic response to TNT in locally advanced rectal cancer, using the neoadjuvant rectal (NAR) score and pathologic complete response (pCR) rate.
methodsThis retrospective cohort study used the National Cancer Database to identify adults diagnosed in 2023 with clinical stage Ⅱ-Ⅲ rectal adenocarcinoma who received TNT followed by proctectomy. Smoking status at diagnosis was categorized as never, current, or former. Primary outcomes were favorable NAR score (< 8) and pCR (ypT0N0).
resultsAmong 1767 patients, 49.7% were never smokers, 30.5% former, and 19.8% current smokers. Rates of favorable NAR score and pCR were highest among never smokers (33.4 and 21.7%), intermediate among former smokers (28.8 and 19.9%), and lowest among current smokers (25.5 and 16.3%). On multivariable analysis, current smoking was associated with lower odds of favorable NAR score than was never smoking (odds ratio 0.59; 95% confidence interval 0.40-0.86). A similar trend was seen for pCR, though this did not reach statistical significance (odds ratio 0.58; 95% confidence interval 0.34-1.00). Former smoking was not significantly different from never smoking in terms of a favorable NAR score or pCR.
conclusionsCurrent smoking status was independently associated with lower rates of response to TNT in locally advanced rectal cancer, whereas former smoking was not when compared with never smoking. These findings identify active tobacco exposure as a potential modifiable risk factor.
Indexed as
Identifiers
42909812What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.